Characterization of Chemical Interactions between Clinical Drugs and the Oral Bacterium, <i>Corynebacterium matruchotii</i>, via Bioactivity-HiTES
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Da Yeong | - |
dc.contributor.author | Kim, Jonghwan | - |
dc.contributor.author | Lee, Gyu Sung | - |
dc.contributor.author | Park, Sehwan | - |
dc.contributor.author | Song, Jeongwon | - |
dc.contributor.author | Lee, Bum Soo | - |
dc.contributor.author | Lee, Seoung Rak | - |
dc.contributor.author | Kim, Ki Hyun | - |
dc.contributor.author | Kim, Chung Sub | - |
dc.date.accessioned | 2024-04-29T00:00:31Z | - |
dc.date.available | 2024-04-29T00:00:31Z | - |
dc.date.issued | 2024-03-21 | - |
dc.identifier.issn | 1554-8929 | - |
dc.identifier.issn | 1554-8937 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/110535 | - |
dc.description.abstract | In the field of natural product research, the rediscovery of already-known compounds is one of the significant issues hindering new drug development. Recently, an innovative approach called bioactivity-HiTES has been developed to overcome this limitation, and several new bioactive metabolites have been successfully characterized by this method. In this study, we applied bioactivity-HiTES to Corynebacterium matruchotii, the human oral bacterium, with 3120 clinical drugs as potential elicitors. As a result, we identified two cryptic metabolites, methylindole-3-acetate (MIAA) and indole-3-acetic acid (IAA), elicited by imidafenacin, a urinary antispasmodic drug approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). MIAA showed weak antibacterial activity against a pulmonary disease-causing Mycobacterium conceptionense with an IC50 value of 185.7 mu M. Unexpectedly, we also found that C. matruchotii metabolized fludarabine phosphate, a USFDA-approved anticancer drug, to 2-fluoroadenine which displayed moderate antibacterial activity against both Bacillus subtilis and Escherichia coli, with IC50 values of 8.9 and 20.1 mu M, respectively. Finally, acelarin, a prodrug of the anticancer drug gemcitabine, was found to exhibit unreported antibacterial activity against B. subtilis with an IC50 value of 33.6 mu M through the bioactivity-HiTES method as well. These results indicate that bioactivity-HiTES can also be applied to discover biotransformed products in addition to finding cryptic metabolites in microbes. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.title | Characterization of Chemical Interactions between Clinical Drugs and the Oral Bacterium, <i>Corynebacterium matruchotii</i>, via Bioactivity-HiTES | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1021/acschembio.3c00798 | - |
dc.identifier.scopusid | 2-s2.0-85188533569 | - |
dc.identifier.wosid | 001189964200001 | - |
dc.identifier.bibliographicCitation | ACS CHEMICAL BIOLOGY, v.19, no.4, pp 973 - 980 | - |
dc.citation.title | ACS CHEMICAL BIOLOGY | - |
dc.citation.volume | 19 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 973 | - |
dc.citation.endPage | 980 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.subject.keywordPlus | BIOTRANSFORMATION | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | MICROBES | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.